Formulation and characterization of CMPI nanoparticles for enhanced targeting of brain nicotinic receptors by positive allosteric modulator
Abstract 3-(2-Chlorophenyl)-5-(5-methyl-1-(piperidin-4-yl)-1 H-pyrazol-4-yl)isoxazole (CMPI) is a nicotinic acetylcholine receptor (nAChRs), one of the most subtype-selective a positive allosteric modulator (PAM) of nicotinic acetylcholine receptors (nAChRs). CMPI that preferentially potentiates the...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-02-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-80935-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823862497470316544 |
|---|---|
| author | Rahma Aly Shoukath Sulthana Robert Beaudoin Ayman K. Hamouda Santosh Aryal |
| author_facet | Rahma Aly Shoukath Sulthana Robert Beaudoin Ayman K. Hamouda Santosh Aryal |
| author_sort | Rahma Aly |
| collection | DOAJ |
| description | Abstract 3-(2-Chlorophenyl)-5-(5-methyl-1-(piperidin-4-yl)-1 H-pyrazol-4-yl)isoxazole (CMPI) is a nicotinic acetylcholine receptor (nAChRs), one of the most subtype-selective a positive allosteric modulator (PAM) of nicotinic acetylcholine receptors (nAChRs). CMPI that preferentially potentiates the (α4)3(β2)2 nAChR, the major nAChR subtype in the cortex and as such carries potential experimental and therapeutic applications. Maximizing delivery of CMPI would enhance its interaction with brain nAChRs that are associated with the desired therapeutic effects while avoiding interactions with peripheral nAChRs that are associated with undesired side effects is critical to the development of nAChR PAM-based therapeutics. Towards this endeavor, this study aims to explore nanoformulation strategies to maximize delivery of CMPI. A biodegradable and biocompatible, the US-FDA-approved, poly(l-lactic-co-glycolic) acid (PLGA) was used to engineer nanoparticles (NPs) to solubilize CMPI in its hydrophobic core in an aqueous environment using the nanoprecipitation with the drug loading content of 10 ± 1.2% by weight of NPs. Thus, synthesized polymeric NPs were characterized for their colloidal properties and biological activities. The hydrodynamic size of these NPs was found to range from 60 to 150 nm and are stable for a prolonged period in biological media. An in-vitro drug release study was conducted to envision a sustained release of CMPI under physiological conditions, which shows distinct kinetics of CMPI under experimental conditions in which released drugs from NPs were collected using dialysis techniques. These NPs were found to be highly biocompatible when challenged against the human embryonic kidney-293 (HEK-293) cell line that stably expressed α4β2 (HEK-α4β2) nAChRs in a wide range of concentrations. In this pilot study, NPs were further labeled with Alexa fluorophore to track and study cellular uptake using fluorescence microscopy, which showed efficient uptake by HEK-α4β2 cells. Given the superiority of the nanoparticulate system in drug delivery and the unique role of CMPI, we hope this study will help in the development of nAChR PAM formulations that have superior pharmacokinetic profiles, especially their brain bioavailability. |
| format | Article |
| id | doaj-art-8ee2fe3a07e1469b83f760098beda7ee |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-8ee2fe3a07e1469b83f760098beda7ee2025-02-09T12:30:59ZengNature PortfolioScientific Reports2045-23222025-02-0115111310.1038/s41598-024-80935-9Formulation and characterization of CMPI nanoparticles for enhanced targeting of brain nicotinic receptors by positive allosteric modulatorRahma Aly0Shoukath Sulthana1Robert Beaudoin2Ayman K. Hamouda3Santosh Aryal4Department of Pharmaceutical Sciences and Health Outcomes, The Ben and Maytee Fisch College of Pharmacy, The University of Texas at TylerDepartment of Pharmaceutical Sciences and Health Outcomes, The Ben and Maytee Fisch College of Pharmacy, The University of Texas at TylerDepartment of Pharmaceutical Sciences and Health Outcomes, The Ben and Maytee Fisch College of Pharmacy, The University of Texas at TylerDepartment of Pharmaceutical Sciences and Health Outcomes, The Ben and Maytee Fisch College of Pharmacy, The University of Texas at TylerDepartment of Pharmaceutical Sciences and Health Outcomes, The Ben and Maytee Fisch College of Pharmacy, The University of Texas at TylerAbstract 3-(2-Chlorophenyl)-5-(5-methyl-1-(piperidin-4-yl)-1 H-pyrazol-4-yl)isoxazole (CMPI) is a nicotinic acetylcholine receptor (nAChRs), one of the most subtype-selective a positive allosteric modulator (PAM) of nicotinic acetylcholine receptors (nAChRs). CMPI that preferentially potentiates the (α4)3(β2)2 nAChR, the major nAChR subtype in the cortex and as such carries potential experimental and therapeutic applications. Maximizing delivery of CMPI would enhance its interaction with brain nAChRs that are associated with the desired therapeutic effects while avoiding interactions with peripheral nAChRs that are associated with undesired side effects is critical to the development of nAChR PAM-based therapeutics. Towards this endeavor, this study aims to explore nanoformulation strategies to maximize delivery of CMPI. A biodegradable and biocompatible, the US-FDA-approved, poly(l-lactic-co-glycolic) acid (PLGA) was used to engineer nanoparticles (NPs) to solubilize CMPI in its hydrophobic core in an aqueous environment using the nanoprecipitation with the drug loading content of 10 ± 1.2% by weight of NPs. Thus, synthesized polymeric NPs were characterized for their colloidal properties and biological activities. The hydrodynamic size of these NPs was found to range from 60 to 150 nm and are stable for a prolonged period in biological media. An in-vitro drug release study was conducted to envision a sustained release of CMPI under physiological conditions, which shows distinct kinetics of CMPI under experimental conditions in which released drugs from NPs were collected using dialysis techniques. These NPs were found to be highly biocompatible when challenged against the human embryonic kidney-293 (HEK-293) cell line that stably expressed α4β2 (HEK-α4β2) nAChRs in a wide range of concentrations. In this pilot study, NPs were further labeled with Alexa fluorophore to track and study cellular uptake using fluorescence microscopy, which showed efficient uptake by HEK-α4β2 cells. Given the superiority of the nanoparticulate system in drug delivery and the unique role of CMPI, we hope this study will help in the development of nAChR PAM formulations that have superior pharmacokinetic profiles, especially their brain bioavailability.https://doi.org/10.1038/s41598-024-80935-9NanomedicineNanoformulationCMPI, Poly(l-lactic-co-glycolic) acidDrug delivery system, inhibitor |
| spellingShingle | Rahma Aly Shoukath Sulthana Robert Beaudoin Ayman K. Hamouda Santosh Aryal Formulation and characterization of CMPI nanoparticles for enhanced targeting of brain nicotinic receptors by positive allosteric modulator Scientific Reports Nanomedicine Nanoformulation CMPI, Poly(l-lactic-co-glycolic) acid Drug delivery system, inhibitor |
| title | Formulation and characterization of CMPI nanoparticles for enhanced targeting of brain nicotinic receptors by positive allosteric modulator |
| title_full | Formulation and characterization of CMPI nanoparticles for enhanced targeting of brain nicotinic receptors by positive allosteric modulator |
| title_fullStr | Formulation and characterization of CMPI nanoparticles for enhanced targeting of brain nicotinic receptors by positive allosteric modulator |
| title_full_unstemmed | Formulation and characterization of CMPI nanoparticles for enhanced targeting of brain nicotinic receptors by positive allosteric modulator |
| title_short | Formulation and characterization of CMPI nanoparticles for enhanced targeting of brain nicotinic receptors by positive allosteric modulator |
| title_sort | formulation and characterization of cmpi nanoparticles for enhanced targeting of brain nicotinic receptors by positive allosteric modulator |
| topic | Nanomedicine Nanoformulation CMPI, Poly(l-lactic-co-glycolic) acid Drug delivery system, inhibitor |
| url | https://doi.org/10.1038/s41598-024-80935-9 |
| work_keys_str_mv | AT rahmaaly formulationandcharacterizationofcmpinanoparticlesforenhancedtargetingofbrainnicotinicreceptorsbypositiveallostericmodulator AT shoukathsulthana formulationandcharacterizationofcmpinanoparticlesforenhancedtargetingofbrainnicotinicreceptorsbypositiveallostericmodulator AT robertbeaudoin formulationandcharacterizationofcmpinanoparticlesforenhancedtargetingofbrainnicotinicreceptorsbypositiveallostericmodulator AT aymankhamouda formulationandcharacterizationofcmpinanoparticlesforenhancedtargetingofbrainnicotinicreceptorsbypositiveallostericmodulator AT santosharyal formulationandcharacterizationofcmpinanoparticlesforenhancedtargetingofbrainnicotinicreceptorsbypositiveallostericmodulator |